Equity proceeds of CA$22M+ raised during 2022 fiscal year Phase 1 clinical trial dosing of proprietary compound, NVG-291, is complete and data analysis is ongoing Phase 1b/2a clinical trial of… Read More
TORONTO, ON — The Gairdner Foundation is pleased to announce the 2023 Canada Gairdner Award laureates, recognizing some of the world’s most significant biomedical and global health research and discoveries…. Read More
VANCOUVER, BC – Gandeeva Therapeutics, Inc., a precision medicine company focused on designing and developing novel therapeutics guided by cryogenic electron microscopy (cryo-EM) and machine learning, announced today the initiation… Read More
VANCOUVER, BC — A Vancouver-based therapeutics company has begun a second Phase II trial of its novel long lasting non-opioid pain medication, with a specific focus on treating Chronic Scrotal… Read More
VANCOUVER, BC — Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, is pleased to announce Dr. Chris Bond has been promoted to… Read More
